Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Despite new treatments for hepatitis C virus (HCV) infection, IFNα-based regimens still have clinical relevance in special populations of patients and remain the only therapeutic option for many patients. 28440692

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Patients were infected with hepatitis C virus (HCV) genotype 1b and were previous null responders/relapsers to interferon-alpha/ribavirin (IFN/RBV). 26937151

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα. 26733671

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Between January 2006 and June 2012, a total of 180 patients with chronic infections of G2 hepatitis C virus (HCV) were treated with response-guided Peg-IFNα/RBV therapy. 25852275

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE However, IFN-λ, a type III IFN with limited receptor expression in hepatic cells, efficiently inhibits HCV (Hepatitis C virus) replication in vivo with potentially less side effects than IFN-α. 26193702

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Impaired induction of IL28B, related to IFNλ4 expression in PBMCs of IL28B-unfavorable patients, is associated with nonresponse to IFNα-based therapy for hepatitis C viral infection. 25611696

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Our results demonstrated that ISG15 impairs HCV RNA replication in both the presence and absence of IFN stimulation, consistent with an antiviral role for ISG15 during HCV infection. 26361997

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Genetic polymorphisms within the interferon lambda (IFN-λ) region are strongly associated with hepatitis C virus (HCV) clearance; the IFNL4-ΔG/TT (rs368234815) polymorphism, which controls the generation of IFN-λ4 protein, is more strongly associated with HCV clearance than rs12979860 (the 'IL28B variant'). 26186989

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE The impact of exposure to interferon-alpha (IFN-α) on gene expression in peripheral blood mononuclear cells (PBMC) from hepatitis C virus (HCV)-infected and healthy individuals was investigated to recognize whether their PBMC differ in expression of IFN-inducible genes (ISGs) following treatment with IFN-α2b. 25765354

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE The addition of hepatitis C virus (HCV) NS3/4A protease inhibitors to pegylated-interferon alpha (PEG-IFNα) and ribavirin (triple therapy) has greatly improved treatment outcome. 26095167

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Using hepatitis C virus (HCV) population sequence analysis, we retrospectively investigated the prevalence of baseline nonstructural 3 (NS3) RAVs in a multicenter cohort of poor IFN-RBV responders (i.e., prior null responders or patients with a viral load decrease of <1 log IU/ml during the pegIFN-RBV lead-in phase). 25926499

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations. 26156630

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122). 25914481

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE The single nucleotide polymorphism located within the IFNL3 (also known as IL28B) promoter is one of the host factors associated with hepatitis C virus (HCV) clearance by interferon (IFN)-α therapy; however the mechanism remains unknown. 26896692

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Thus, SVR in chronic HCV infection is associated with a strong IFNα-induced cytokine response, which might allow for the early prediction of treatment efficacy in HCV infection. 26503984

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Nitazoxanide (NTZ) plus pegylated interferon and ribavirin (Peg-IFN/RBV) improved the sustained virological response (SVR) achieved with Peg-IFN/RBV in hepatitis C virus genotype 4 (HCV-4)-monoinfected patients. 26640956

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE To assess the accuracy and cost-effectiveness of the automated Abbott ARCHITECT HCV Ag assay (Wiesbaden, Germany) in monitoring response to pagylated interferon (PEG-IFN) and ribavirin therapy for chronic HCV genotype 4 (G4). 26018116

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. 26581744

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Several such GWAS have highlighted the IFN-λ locus on chromosome 19q13 as an area of genetic variation significantly associated with hepatitis C virus (HCV) infection, and the rs12979860 genotype can be used in clinical practice as a biomarker for predicting a successful response to treatment with pegylated IFN and ribavarin. 25634147

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Hepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. 25965701

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. 26725897

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE Although the mechanisms underlying the different outcomes of HCV infection are not fully understood, innate immune responses seem to have a critical impact on the outcome of HCV infection, as demonstrated by the prognostic value of IFN-λ gene polymorphisms among patients with chronic HCV infection. 26457705

2016

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 AlteredExpression BEFREE Set7 facilitates hepatitis C virus replication via enzymatic activity-dependent attenuation of the IFN-related pathway. 25681344

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 Biomarker BEFREE We demonstrated a marked polarization of NK cells toward cytotoxicity in response to IFN-α stimulation in patients with hepatitis C. That TRAIL up-regulation was present, particularly in patients with the IFNL3-TT allele, was supported by a shift in the pSTAT-1:pSTAT-4 ratios toward pSTAT-1. 26034208

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019196
Disease: Hepatitis C
Hepatitis C
0.100 GeneticVariation BEFREE The current standard of care for treatment-naïve HCV-1 is the second-wave PI, sofosbuvir, plus PEG-IFN/RBV and sofosbuvir plus the second-wave nucleotide inhibitor simeprevir with or without RBV in treatment-experienced HCV-1 patients. 25529082

2015